share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股sec公告 ·  05/02 16:31
Moomoo AI 已提取核心信息
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has announced significant changes to its executive team in a recent Form 8-K filing with the SEC. Timothy Lu, M.D., Ph.D., currently serving as the CEO and President, has been appointed as the interim principal financial officer and principal accounting officer, effective May 4, 2024. This appointment follows the Board's approval on April 26, 2024, and will last until a permanent successor is appointed or until Lu's earlier departure from the role. Additionally, Yvonne Li has been appointed as the Interim Chief Financial Officer, also effective May 4, 2024. Li's appointment will become official immediately after the filing of the company's Quarterly Report for the fiscal quarter ended March 31, 2024. In conjunction with her appointment, Li has entered into a consulting agreement with Senti Biosciences, which includes a consulting fee of $350 per hour and a maximum aggregate payment of $370,000. The company plans to provide a full description of the Li Consulting Agreement in its upcoming Quarterly Report for the fiscal quarter ending June 30, 2024.
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has announced significant changes to its executive team in a recent Form 8-K filing with the SEC. Timothy Lu, M.D., Ph.D., currently serving as the CEO and President, has been appointed as the interim principal financial officer and principal accounting officer, effective May 4, 2024. This appointment follows the Board's approval on April 26, 2024, and will last until a permanent successor is appointed or until Lu's earlier departure from the role. Additionally, Yvonne Li has been appointed as the Interim Chief Financial Officer, also effective May 4, 2024. Li's appointment will become official immediately after the filing of the company's Quarterly Report for the fiscal quarter ended March 31, 2024. In conjunction with her appointment, Li has entered into a consulting agreement with Senti Biosciences, which includes a consulting fee of $350 per hour and a maximum aggregate payment of $370,000. The company plans to provide a full description of the Li Consulting Agreement in its upcoming Quarterly Report for the fiscal quarter ending June 30, 2024.
特拉华州注册成立的生物技术公司Senti Biosciences, Inc. 在最近向美国证券交易委员会提交的8-K表格中宣布了其执行团队的重大变动。Timothy Lu，医学博士，现任首席执行官兼总裁，已被任命为临时首席财务官兼首席会计官，自2024年5月4日起生效。这项任命是在董事会于2024年4月26日批准之后进行的，将持续到任命永久继任者或卢提前离职为止。此外，李怡被任命为临时首席财务官，同样自2024年5月4日起生效。在公司提交截至2024年3月31日的财季季度报告后，李的任命将立即正式生效。在接受任命的同时，李还与Senti Biosciences签订了咨询协议，其中包括每小时350美元的咨询费和最高37万美元的总付款。该公司计划在即将发布的截至2024年6月30日的财季季度报告中对李咨询协议进行全面描述。
特拉华州注册成立的生物技术公司Senti Biosciences, Inc. 在最近向美国证券交易委员会提交的8-K表格中宣布了其执行团队的重大变动。Timothy Lu，医学博士，现任首席执行官兼总裁，已被任命为临时首席财务官兼首席会计官，自2024年5月4日起生效。这项任命是在董事会于2024年4月26日批准之后进行的，将持续到任命永久继任者或卢提前离职为止。此外，李怡被任命为临时首席财务官，同样自2024年5月4日起生效。在公司提交截至2024年3月31日的财季季度报告后，李的任命将立即正式生效。在接受任命的同时，李还与Senti Biosciences签订了咨询协议，其中包括每小时350美元的咨询费和最高37万美元的总付款。该公司计划在即将发布的截至2024年6月30日的财季季度报告中对李咨询协议进行全面描述。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息